These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29091298)

  • 1. The mechanism and potential targets of class II HDACs in angiogenesis.
    Hou F; Li D; Yu H; Kong Q
    J Cell Biochem; 2018 Apr; 119(4):2999-3006. PubMed ID: 29091298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of histone deacetylase inhibitors on kidney disease.
    Chun P
    Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair.
    Deng B; Luo Q; Halim A; Liu Q; Zhang B; Song G
    DNA Cell Biol; 2020 Feb; 39(2):167-176. PubMed ID: 31808715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic control of tumor angiogenesis.
    Ribatti D; Tamma R
    Microcirculation; 2020 Apr; 27(3):e12602. PubMed ID: 31863494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical HDACs in the regulation of neuroinflammation.
    Dai Y; Wei T; Shen Z; Bei Y; Lin H; Dai H
    Neurochem Int; 2021 Nov; 150():105182. PubMed ID: 34509559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.
    Zhou B; Margariti A; Zeng L; Xu Q
    Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
    Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
    Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
    Cantley MD; Fairlie DP; Bartold PM; Rainsford KD; Le GT; Lucke AJ; Holding CA; Haynes DR
    J Cell Physiol; 2011 Dec; 226(12):3233-41. PubMed ID: 21344383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Phosphorylated HDAC4 in Stroke-Induced Angiogenesis.
    Liu J; Zhou X; Li Q; Zhou SM; Hu B; Hu GW; Niu X; Guo SC; Wang Y; Deng ZF
    Biomed Res Int; 2017; 2017():2957538. PubMed ID: 28127553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer.
    Chiaradonna F; Cirulli C; Palorini R; Votta G; Alberghina L
    Antioxid Redox Signal; 2015 Jul; 23(1):30-50. PubMed ID: 24483782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
    Gomazkov OA
    Eksp Klin Farmakol; 2015; 78(11):35-44. PubMed ID: 27017704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Progress on Histone Deacetylases Regulating Programmed Cell Death in Atherosclerosis.
    Zhou G; Liu Y; Wu H; Zhang D; Yang Q; Li Y
    J Cardiovasc Transl Res; 2024 Apr; 17(2):308-321. PubMed ID: 37821683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics.
    Nguyen MP; Lee S; Lee YM
    Arch Pharm Res; 2013 Mar; 36(3):252-63. PubMed ID: 23440580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.